Targacept signs antidepressant deal with AstraZeneca
03 December 2009
Sukaina Virji
AstraZeneca and
Targacept have signed a collaboration and licence agreement for the global development and commercialisation of TC-5214, Targacept's late-stage investigational product for major depressive disorder (MDD).
TC-5214, a nicotinic channel blocker that is thought to treat depression...
Please Login to read the full article.
03 December 2009
Sukaina Virji
TC-5214, a nicotinic channel blocker that is thought to treat depression...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Targacept plans $75M fund raising, as it will develop PhII schizophrenia candidate on its own
- AstraZeneca to take $381.5 million charge after two major trial failures
- Alkermes' PhII ALKS-5461: new mechanism, opiate receptor modulation, for refractory depression
- Purdue opts in and plans to launch Transcept’s Intermezzo in the US in 2Q 2012
COMMENT
Other Informa Comment
EVENTS
Today
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
